This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MSST-91102 | |
|---|---|
| Name | MSST-91102 |
| Caption | Structural schematic of MSST-91102 |
| Legal status | Investigational |
| Routes of administration | Oral; Intravenous |
| Molecular formula | C20H24N4O3 |
| Molar mass | 368.43 g·mol−1 |
MSST-91102 is a synthetic small-molecule therapeutic developed for targeted modulation of intracellular signaling pathways implicated in inflammatory and proliferative disorders. Initially characterized in preclinical studies, MSST-91102 attracted attention from academic groups and biotechnology firms for its selective binding profile and oral bioavailability. Investigations involved collaborations among research institutes, contract research organizations, and pharmaceutical developers.
MSST-91102 was discovered during a lead-optimization program that involved screening libraries at the intersection of medicinal chemistry and structural biology, with contributions from teams at Massachusetts Institute of Technology, Harvard University, and a biotechnology start-up incubated near Cambridge, Massachusetts. Early reports were presented at meetings organized by the American Association for Cancer Research, the American Society for Pharmacology and Experimental Therapeutics, and the Biophysical Society. Patent filings were prosecuted before the United States Patent and Trademark Office and the European Patent Office, with licensing negotiations involving multinational firms headquartered in Basel and Tokyo.
MSST-91102 is a heterocyclic compound containing substituted amide and methoxy functionality. Analytical characterization employed techniques standardized by laboratories such as National Institute of Standards and Technology and instrumentation from Agilent Technologies and Bruker Corporation for NMR and mass spectrometry. Crystallographic studies were coordinated with beamlines at synchrotron facilities including Diamond Light Source and Advanced Photon Source, enabling refinement of atomic coordinates according to protocols used at the Protein Data Bank. Physical properties such as solubility, pKa, and partition coefficient were measured following guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
MSST-91102 functions as a selective modulator of a kinase cascade implicated in cell proliferation and immune signaling. Biochemical assays utilized recombinant proteins from suppliers like Cayman Chemical and binding studies employed surface plasmon resonance instruments from GE Healthcare Life Sciences. Cellular pathway mapping referenced canonical nodes characterized in databases curated by European Bioinformatics Institute and National Center for Biotechnology Information. Preclinical mode-of-action investigations were discussed in the context of signaling frameworks elaborated by researchers affiliated with Stanford University, Johns Hopkins University, and University of California, San Francisco.
Synthesis of MSST-91102 followed convergent routes combining palladium-catalyzed cross-coupling and amide-bond formation; catalytic systems referenced protocols developed at Scripps Research and methodologies popularized by groups at University of Cambridge. Process development and scale-up were optimized in pilot plants operated by contract manufacturers such as Catalent and Patheon, applying quality systems aligned with European Medicines Agency and Food and Drug Administration expectations. Analytical validation used chromatographic methods standardized by United States Pharmacopeia and stability testing conformed to International Conference on Harmonisation guidelines.
Pharmacokinetic profiling involved studies in rodent and non-rodent species, performed at contract research organizations accredited by Association for Assessment and Accreditation of Laboratory Animal Care International. Parameters measured included absorption, distribution, metabolism, and excretion, with metabolic pathways characterized using microsomes from suppliers like Corning Incorporated. Toxicology evaluations encompassed acute, subchronic, and genotoxicity assays following protocols from Organisation for Economic Co-operation and Development test guidelines; safety pharmacology referenced standards set by the European Federation of Pharmaceutical Industries and Associations. Adverse-effect signals were discussed in preclinical reports reviewed by institutional animal care and use committees at Yale University and University of Pennsylvania.
MSST-91102 entered Phase I clinical trials at clinical research centers affiliated with Mayo Clinic and Cleveland Clinic to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. Subsequent early-phase studies explored indications guided by translational programs at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute for proliferative disorders, and rheumatology collaborations at Hospital for Special Surgery for inflammatory disease. Trial designs registered with ClinicalTrials.gov incorporated endpoints consistent with guidance from the European Medicines Agency and Food and Drug Administration for first-in-human trials.
As of the latest regulatory filings, MSST-91102 maintains an investigational status with submissions under review by agencies including the Food and Drug Administration and the European Medicines Agency. Regulatory documentation followed Common Technical Document organization and pharmacovigilance practices aligned with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Safety monitoring in clinical studies adhered to institutional review board oversight at centers such as Johns Hopkins Medicine and reporting frameworks recommended by the World Health Organization and the International Conference on Harmonisation.
Category:Investigational drugs